Compare Heron Therapeutics Inc (HRTX) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Logitech International SA — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Logitech International SA trades at $98.4 (market cap $14.46B). The key difference: Logitech International SA is far larger — about 212.6× Heron Therapeutics Inc's market cap, and Logitech International SA pays a 1.63% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Logitech International SA for 92 Days on average.
| HRTX | LOGI | |
|---|---|---|
Market Cap | $68.01M | $14.46B |
Volume | 1,891,941 | 349,547 |
Sector | Health | Technology |
52-Week High | $1.49 | $126.69 |
52-Week Low | $0.27 | $85.84 |
Typical Hold Time | 35 Days | 92 Days |
Enterprise Value | $174.75M | $12.79B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Logitech (LOGI) trades at $100.70, down 1.45% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $107.00. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.85 surpassing the $1.26 estimate. The company maintains strong profitability, including a 16.28% net income margin and 35.29% ROE, and has announced new product launches like the Zone Vibe Pro headset and a partnership with SEGA.
The outlook is supported by solid fundamentals and positive product news, but risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is mixed, with a Hold consensus, suggesting cautious optimism. Upside potential exists if the company continues its earnings beat streak and navigates supply chain challenges effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
